A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Latest Information Update: 06 Aug 2024
At a glance
- Drugs Belinostat (Primary) ; Talazoparib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Male breast cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- 02 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
- 02 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.
- 15 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.